Research Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global testBy Healthcare Propulsion StaffAugust 18, 20260 Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout. The…
